novonordisk
The weight-loss drug semaglutide - commonly sold under the brand names Ozempic and Wegovy - reduced cardiovascular events such as stroke and heart attack in adults with preexisting disease independent of weight loss. It also helped people keep their weight down for at least four years. That is according to two new analyses of a large trial presented at the European Congress on Obesity in Venice on Monday. Semaglutide is the main active ingredient in the popular weight-loss jabs Ozempic and Wegovy. It mimics the GLP-1 hormone which can signal that your body is full. The analyses looked at the S...
Euronews (English)
In plans aimed at revolutionising healthcare and other life sciences, Novo Holdings is investing DKK 1.4 billion (€188 million) in building a hub of start-ups focused on new technologies including quantum computing. Quantum computers, capable of making scientific calculations that would otherwise take most computers thousands of years, can potentially speed up the development of pharmaceuticals and other life sciences. Novo Holdings is the parent company of Europe's most valuable firm, Novo Nordisk, known for its weight-loss medication Wegovy and Ozempic, a diabetes drug. "Quantum technologies...
Euronews (English)
Profit increased in the first quarter for Danish pharmaceutical company Novo Nordisk compared to the previous year. First-quarter net profit increased by 28% to 25.41 billion Danish kroner ($3 billion), the company reported. Earnings per share increased by 29% to 5.68 kroner. Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner. First quarter sales increased by 22% measured in kroner and by 24% at CER to 65.35 billion kroner in the first three months of 2024. For 2024, the company now expects operating profit growth to be 22% to 30% at ...
DPA International
Profit increased in the first quarter for Danish pharmaceutical company Novo Nordisk compared to the previous year. First-quarter net profit increased by 28% to 25.41 billion Danish kroner ($3 billion), the company reported. Earnings per share increased by 29% to 5.68 kroner. Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner. First quarter sales increased by 22% measured in kroner and by 24% at CER to 65.35 billion kroner in the first three months of 2024. For 2024, the company now expects operating profit growth to be 22% to 30% at ...
DPA
Profit increased in the first quarter for Danish pharmaceutical company Novo Nordisk compared to the previous year. First-quarter net profit increased by 28% to 25.41 billion Danish kroner ($3 billion), the company reported. Earnings per share increased by 29% to 5.68 kroner. Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner. First quarter sales increased by 22% measured in kroner and by 24% at CER to 65.35 billion kroner in the first three months of 2024. For 2024, the company now expects operating profit growth to be 22% to 30% at ...
DPA Breaking News
Danish pharmaceutical firm Novo Nordisk said it has agreed to acquire the biotech company Cardior Pharmaceuticals, based in Hanover, Germany, for up to €1.03 billion ($1.01 billion), according to a joint announcement on Monday. Novo Nordisk, known primarily for its diabetes business and the weight-loss drugs Wegovy and Ozempic, intends to strengthen its presence in the field of cardiovascular diseases. The focus is particularly on a promising drug from Cardior for heart failure. Cardior was founded in 2016 as a spin-off from Hanover Medical School. The heart disease therapy developed by the st...
DPA International
Danish pharmaceutical firm Novo Nordisk said it has agreed to acquire the biotech company Cardior Pharmaceuticals, based in Hanover, Germany, for up to €1.03 billion ($1.01 billion), according to a joint announcement on Monday. Novo Nordisk, known primarily for its diabetes business and the weight-loss drugs Wegovy and Ozempic, intends to strengthen its presence in the field of cardiovascular diseases. The focus is particularly on a promising drug from Cardior for heart failure. Cardior was founded in 2016 as a spin-off from Hanover Medical School. The heart disease therapy developed by the st...
DPA
Danish pharmaceutical firm Novo Nordisk said it has agreed to acquire the biotech company Cardior Pharmaceuticals, based in Hanover, Germany, for up to €1.03 billion ($1.01 billion), according to a joint announcement on Monday. Novo Nordisk, known primarily for its diabetes business and the weight-loss drugs Wegovy and Ozempic, intends to strengthen its presence in the field of cardiovascular diseases. The focus is particularly on a promising drug from Cardior for heart failure. Cardior was founded in 2016 as a spin-off from Hanover Medical School. The heart disease therapy developed by the st...
DPA Breaking News
Der dänische Pharmakonzern Novo Nordisk übernimmt für mehr als eine Milliarde Euro das Biotech-Unternehmen Cardior Pharmaceuticals aus Hannover. Beide Unternehmen hätten vereinbart, dass Novo Nordisk bis zu 1,025 Milliarden Euro für das Start-up zahlen werde, hieß es in einer gemeinsamen Mitteilung. Damit wolle Novo Nordisk, bekannt vor allem für sein Diabetesgeschäft sowie die Abnehmmittel Wegovy und Ozempic, seine Präsenz im auf dem Gebiet der Herz-Kreislauf-Erkrankungen stärken. Im Fokus steht insbesondere ein vielversprechendes Medikament der Hannoveraner gegen Herzinsuffizienz. Cardior wa...
DPA (German)
Key Points Wegovy, Novo Nordisk’s weight-loss drug, reduces cardiovascular risk in overweight adults.Patients in the Wegovy clinical trial showed 20% less likelihood of major cardiovascular events.Bank of America notes the news is a “game changer for payor debate on obesity.”B of A analysts anticipate further data to be presented at the American Heart Association conference in November.Wall Street predicts 49% earnings rise in 2023 and 18% in 2024 for Novo.5 stocks we like better than Novo Nordisk A/SWeight-loss drugs are the pharmaceutical industry’s equivalent of AI, in the sense of being a ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら